The global pneumonia therapeutics market size is expected to reach USD 4.26 billion by 2030, registering a CAGR of 9.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. This market is anticipated to grow at an unprecedented rate owing to the increasing prevalence of pneumococcal disease globally. The increasing demand for pneumonia therapeutics is a result of unmet clinical needs in emerging as well as developed regions. Increasing focus of healthcare organizations on raising awareness and issuing guidelines for efficient management of pneumococcal disease is predicted to broaden the scope for growth over the coming years.For instance, Infectious Diseases Society of America/American Thoracic Society has issued guidelines on the management of community-acquired pneumonia. According to a white paper released by American Academy of Family Physicians, adherence to these guidelines has resulted in positive patient outcomes during the treatment of community-acquired bacterial pneumonia in patients.
Moreover, growing R&D activities in life sciences are anticipated to create positive impact on the market over the coming years. Consequentially, increase in number of products, currently being reviewed under clinical trials, is anticipated to fuel the overall growth.In the present scenario, there are 12 drugs under investigation in phase III trials, 4 drugs under phase II, and 3 drugs under phase I trial. The aforementioned factors exemplify the consistent efforts being made by the market players. For instance, Omadacycline, a tetracycline under phase III clinical trial, developed by Paratek Pharmaceuticals is being investigated for use in the treatment of ventilator-associated and community-acquired bacterial pneumonia.
Request a free sample copy or view report summary: Pneumonia Therapeutics Market Report
The vaccine segment dominated the market and accounted for a share of 54.1% in 2023. Increasing awareness about the importance of preventive healthcare has significantly boosted the acceptance and demand for pneumonia vaccines.
Hospital-acquired pneumonia (HAP) infection accounted for the largest market revenue share in 2023. Advances in diagnostic tools and technologies have significantly improved the early detection and accurate diagnosis of hospital-acquired pneumonia (HAP), critical for effective patient management and outcomes.
The parental segment held the largest revenue market share in 2023. Parenteral administration can ensure high bioavailability and effective delivery of medications.
The hospitals segment held the largest revenue market share in 2023. Hospitals are the primary segment for treating severe pneumonia cases who require mechanical ventilations.
North America pneumonia therapeutics market held the highest revenue market share of 35.4% in 2023. Ongoing technological advancements in diagnostics and treatment options are a major driver of growth in the North American pneumonia therapeutics market.
Grand View Research has segmented the global pneumonia therapeutics market on the basis of on product, infection, route of administration, end-use, and region:
Pneumonia Therapeutics Product Outlook (Revenue, USD Million, 2018 - 2030)
Drugs
Vaccine
Oxygen Therapy
Pneumonia Therapeutics Infection Outlook (Revenue, USD Million, 2018 - 2030)
Hospital-acquired Pneumonia (HAP)
Community-acquired Pneumonia (CAP)
Ventilator-associated Pneumonia (VAP)
Pneumonia Therapeutics Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Oral
Parenteral
Others
Pneumonia Therapeutics End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Homecare
Specialty Clinics
Others
Pneumonia Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
Saudi Arabia
UAE
South Africa
Kuwait
List of Key Players in the Pneumonia Therapeutics Market
AstraZeneca
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
"The quality of research they have done for us has been excellent..."